Stock Code：1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Fourth Quarter 2023 Investor Conference

March 26, 2024



Safe Harbor Notice

- CCSB’ s presentation contains forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from those contained in the forward-looking statements.
- The forward-looking statements in this release reflect the current belief of CCSB as of the date of this release, we undertake no obligation to update these forward-looking statements for new information, future events or otherwise.

Company Highlight


- **Stock Code:1762**
- **Employee:347 (As of 2023/12/31)**
- **2023 /1/1-12/31 Revenue 2.1 billion**

- **Brief History**
- **Founded in 1964**
  - ✓ First registered and one of the largest bulk pharmaceutical chemical manufacturers in Taiwan
  - ✓ First FDA approved plant (1984) in Taiwan
- **Turning Points**
  - ✓ Formed the New Management Team in 1997, 4 cGMP Plants for Synthetic Products and 2 cGMP Plants for Biotechnology Products
  - ✓ Established US Sales Office- Pharmaports in 2000
  - ✓ Initial public offering on December 20, 2010

Key Strengths

- An API factory with bio-fermentation and chemical synthesis technology and equipment.
- Ensure compliance with and successfully pass inspections by the US FDA and European PIC/S regulations.
- Certified API master file DMFs for a variety of products, Export products are competitive.
- From small batch research and development to mass production of APIs, offering comprehensive one-stop services.

US DMF List



8625 • DEXBROMPHENIRAMINE MALEATE	13080 • METHOCARBAMOL USP	14234 • GUAIFENESIN USP	14235 • PRAVASTATIN SODIUM USP	17399 • RAPAMYCIN	17573 • TRANDOLAPRIL USP
18494 • MYCOPHENOLATE MOFETIL USP	18985 • TACROLIMUS	23213 • TACROLIMUS SD20	24372 • MYCOPHENOLATE MOFETIL HYDROCHLORIDE ANHYDROUS	26271 • ETHYL ICOSAPENTATE	26819 • EVEROLIMUS PRE-MIX USP
27216 • EVEROLIMUS USP	27585 • CASPOFUNGIN ACETATE	31189 • RAPAMYCIN (SIROLIMUS)	31276 • CARFILZOMIB	33333 • MYCOPHENOLATE MOFETIL USP (PROCESS B)	35848 • MYCOPHENOLATE SODIUM USP
35849 • FAVIPIRAVIR	36030 • BARICITINIB	36174 • RIBOCICLIB SUCCINATE	36640 • MIDOSTAURIN	37532 • TOFACITINIB CITRATE	37586 • PALBOCICLIB
37597 • OZANIMOD HYDROCHLORIDE	38111 • EVEROLIMUS B02 USP	38310 • TACROLIMUS (PROCESS B)	38511 • DIFELIKEFALIN ACETATE	39312 • ESLICARBAZEPINE ACETATE	

Key Products

- Active Pharmaceutical Ingredients (API) for brand drugs and generic drugs
  - Tacrolimus：As an immunosuppressant API, it is used to prevent organ transplant rejection.
  - Everolimus：It is used for anticancer drug, cardiovascular stent coating and immunosuppressive dosages.
  - Ethyl Icosapentate：For triglyceride lowering medication.

Consolidated Comprehensive Income Statement

Amount: NT$ Thousand


Year / Item	2023Y		2022Y		YOY
	Amount	%	Amount	%	(%)
Net Sales	$2,086,441	100%	$2,117,144	100%	-1%
Gross Profit	757,308	36%	961,757	45%	-21%
Operating Profit	280,808	13%	463,532	22%	-39%
Profit before Tax	333,486	16%	583,305	28%	-43%
Net Profit	$264,908	13%	$466,140	22%	-43%
Net Profit Attributable to Owners of Company	$264,908	13%	$465,865	22%	-43%
Basic EPS(NT$)	$3.42		$6.01		

2023/1/1-12/31 Sales Distribution By Region


Region/ Product	%	EPAE	EVE	FK506	MMF	RAPA	CAS	MCB
US	68%	●	●		●	●		
Asia	16%		●	●		●		
Europe	11%		●			●	●	●
Taiwan	5%			●				

Share of Revenue by Key Products


2023Y



2022Y



Consolidated Profitability Of The Latest 5 Years



Consolidated Balance Sheet

Amount: NT$ Thousand

Year / Item	2023/12/31 Amount	2023/12/31 %	2022/12/31 Amount	2022/12/31 %
Cash and Cash Equivalents	269,569	5%	300,614	7%
Accounts Receiable	234,933	5%	292,676	7%
Inventory	1,211,026	24%	819,953	18%
Investments accounted for using equity method	961,625	19%	964,937	21%
Property, Plant & Equipment	2,284,333	44%	1,960,581	43%
Total Assets	**5,171,651**	**100%**	**4,564,144**	**100%**
Short and Long Term Loan	1,200,000	24%	600,000	13%
Accounts Payable/Other payables	297,649	6%	403,384	9%
Deferred tax liabilities	258,541	5%	256,221	6%
Total Liabilities	**1,821,417**	**35%**	**1,371,125**	**30%**
Total Shareholder's Equity	**3,350,234**	**65%**	**3,193,019**	**70%**
Debt to Total Asset Ratio	35%		30%	
Current Ratio	215%		236%	

Latest News

Capacity

- Invested in new equipment to enhance the product competitiveness of Caspofungin and Everolimus.


Regulatory

- Accomplished the US DMF application for Eslicarbazepine Acetate.
- Accomplished customer’ s remote on-sited inspections from China, Denmark, Ireland, Switzerland and US.

ESG

- Continue providing care for the elderly in the community from August to November, while continuing to implement ESG social care initiatives.

Future Outlook (1/2)



- Process optimization, strain improvement and capacity increase of key products Everolimus, Tacrolimus and Caspofungin , which will further boost market penetration and share.
- Registration approvals and regulatory change operations are conducted in multiple countries, with the goal of continuously expanding into new markets.
- Short term increase of revenue from CDMO/CMO. Develop the drugs substances in advance and involve the International new drugs R&D.

Future Outlook (2/2)


P4 Products (5-10 years launch)

- CKD-Associated Pruritus
  Difelikefalin Acetate
- Multiple Sclerosis
  Ozanimod HCl
- Genetic Obesity
  Setmelanotide Acetate
- SCLC Myelopreservation Therapy
  Trilaciclib 2HCl
- Diabetes,Type2, Cardiovascular Risk Reduction, Weight Loss
  Semaglutide

P3 Products (3-5 years launch)

- Epilepsy, Seizures
  Eslicarbazepine Acetate, Brivaracetam
- Neurofibromatosis Type 1
  Selumetinib Sulfate
- Hematology
  Eltrombopag Olamine
- Breast Cancer
  Palbociclib, Ribociclib Succinate
- Rheumatoid Arthritis
  Baricitinib, Tofacitinib Citrate

◆ Development Milestones



List of Abbreviations

Abbreviation	Full name	Treatment for
EPAE	Ethyl Icosapentate	Hypertriglyceridemia, Cardiovascular Risk Reduction
EVE	Everolimus	Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma Organ Transplant, Rejection Prophylaxis
FK506	Tacrolimus	Organ Transplant, Rejection Prophylaxis
MMF	Mycophenolate Mofetil	Organ Transplant, Rejection Prophylaxis
RAPA	Rapamycin (Sirolimus)	Immunosuppressant
CAS	Caspofungin Acetate	Antifungal
MCB	Methocarbamol	Muscle relaxant
DFK	Difelikefalin acetate	Chronic Kidney Disease-Associated Pruritus

Always a Team Player







http://www.ccsb.com.tw

Stock Code：1762